News headlines about Vertex Pharmaceuticals (NASDAQ:VRTX) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vertex Pharmaceuticals earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the pharmaceutical company an impact score of 45.141807537452 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern’s analysis:
- Vertex Pharmaceuticals : Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer (4-traders.com)
- Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer (finance.yahoo.com)
- Why Regeneron Pharmaceuticals’ Stock Price Fell (finance.yahoo.com)
- Is Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) PE Ratio A Signal To Sell For Investors? (finance.yahoo.com)
- Vertex Pharmaceuticals (VRTX) Given New $200.00 Price Target at Barclays (americanbankingnews.com)
Vertex Pharmaceuticals stock opened at $162.98 on Friday. The firm has a market cap of $40,516.09, a P/E ratio of 202.00, a PEG ratio of 2.27 and a beta of 1.56. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14. Vertex Pharmaceuticals has a one year low of $106.03 and a one year high of $178.25.
Vertex Pharmaceuticals announced that its Board of Directors has initiated a share repurchase plan on Wednesday, January 31st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the pharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its stock is undervalued.
A number of equities analysts have commented on VRTX shares. HC Wainwright reaffirmed a “hold” rating and set a $103.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 13th. Deutsche Bank started coverage on Vertex Pharmaceuticals in a research note on Tuesday, December 12th. They set a “buy” rating and a $175.00 target price for the company. Oppenheimer boosted their price target on Vertex Pharmaceuticals from $175.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, January 4th. BidaskClub upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, March 13th. Finally, Bank of America restated a “buy” rating and set a $180.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, January 23rd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twenty-five have assigned a buy rating to the company. Vertex Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $183.96.
In related news, CFO Thomas Graney sold 777 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $149.95, for a total value of $116,511.15. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Amit Sachdev sold 13,750 shares of the stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $175.00, for a total value of $2,406,250.00. Following the completion of the transaction, the executive vice president now directly owns 60,412 shares in the company, valued at approximately $10,572,100. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 355,677 shares of company stock worth $56,885,296. Company insiders own 1.80% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was published by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://baseballnewssource.com/2018/03/30/vertex-pharmaceuticals-vrtx-getting-somewhat-favorable-media-coverage-report-shows/1974414.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.